COMMUNIQUÉS West-GlobeNewswire

European Commission approves JASCAYD®, bringing well-tolerated, novel oral treatment for IPF and PPF to the EU
17/07/2026
Not intended for UK and US audiences JASCAYD® (nerandomilast) is the first oral, preferential PDE4B inhibitor approved in the European Union, delivering a novel mechanism of action with antifibrotic and immunomodulatory [...]
Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline
17/07/2026
Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist Dimerix Limited (ASX: DXB) Mission will receive up to US$292 million in [...]
Orion Corporation’s financial reporting and Annual General Meeting in 2027
17/07/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 17 JULY 2026 at 10.30 EEST Orion Corporation’s financial reporting and Annual General Meeting in 2027 Orion Corporation will publish its Financial Statement [...]
Enjoin Reports 923% Average ROI Delivered in Q1 2026
17/07/2026
Photo Courtesy of Enjoin NASHVILLE, Tenn., July 16, 2026 (GLOBE NEWSWIRE) -- Enjoin, a leading tech-enabled provider of Pre-Bill Chart Reviews and trusted revenue integrity partner to health systems and children's [...]
Marketing Veteran Bryan Dulaney is advising SafeSpace Global on Growth Strategy
17/07/2026
NASHVILLE, TN., July 16, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), (“SafeSpace Global” or the “Company”), an AI-powered physical safety and monitoring platform for regulated care environments [...]
Profound Medical to Release Second Quarter 2026 Financial Results on August 6th – Conference Call to Follow
16/07/2026
TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI ( [...]
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
16/07/2026
HONG KONG, July 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the "Company"), a leading provider of over the counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in [...]
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
16/07/2026
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders Concurrent $132 million private investment with participation [...]
Cellution Biologics Inc. Signs Definitive Agreement to Acquire SimpliDerm® Human Hydrated Acellular Dermal Matrix Business from Elutia Inc., Expanding its Allograft Portfolio
16/07/2026
Acquisition marks Cellution Biologics' entry into the U.S. reconstructive surgery market through an established human acellular dermal matrix platform. SimpliDerm ® expands Cellution Biologics' advanced biologics [...]
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
16/07/2026
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platform [...]
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
16/07/2026
BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter
16/07/2026
Trial court denied Company’s motion for a new trial and judgment as a matter of law for unjust enrichment ANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover the value of the [...]
DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation
16/07/2026
Châtillon, France, le 16 juillet 2026 DBV Technologies publie son Rapport Financier Semestriel 2026 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : [...]
Elutia Signs Definitive Agreement to Sell SimpliDerm® in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch
16/07/2026
Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 months Proceeds provide additional non-dilutive capital to advance NXT- [...]
Gyre Therapeutics Appoints Three New Members to its Board of Directors
16/07/2026
SAN DIEGO, July 16, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (“Gyre”, “Gyre Therapeutics” or the “Company”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company with operations in the United [...]
Intuitive Announces Second Quarter Earnings
16/07/2026
SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial [...]
LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
16/07/2026
SCOTTSDALE, Ariz., July 16, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental healthcare, will issue its second quarter 2026 earnings [...]
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
16/07/2026
AUDUBON, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2026 after the [...]
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
17/07/2026
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation 1 Clinically meaningful improvements of protein in urine observed as early as two weeks, with sustained reduction [...]

Pages